Nasdaq

Clearside Biomedical Details Phase 3 Program for CLS-AX in Wet AMD Following Positive FDA Meeting

Receipt of formal meeting minutes from the FDA confirming key elements for two proposed Phase 3 pivotal trials indicates regulatory progress and alignment with the FDA. Positive outcome of the ...
Nasdaq

Clearside Biomedical Highlights CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial at Upcoming Conferences

Clearside Biomedical announces upcoming presentations on CLS-AX sub-group analyses from the ODYSSEY Wet AMD trial at various conferences. Clearside Biomedical, Inc. announced upcoming presentations ...
Seeking Alpha

Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit

Summary: This presentation compared the benefits of TKIs in wet AMD management, focusing on pan-VEGF receptors blockage and extended drug delivery while acknowledging the limitations of current ...
Business Insider

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

- Upcoming Presentations at Angiogenesis and Macula Society Conferences to Feature CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial - - CLS-AX Targets Flexible Dosing of Biologics with Duration of ...